Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

1-year results from a randomized, placebo-controlled trial," by Sherry, et al.(1) and provides the results of per protocol as well as exploratory, post hoc analyses.  The findings suggest that "future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children."

The article indicates that teplizumab treatment may preserve beta cell function as measured by C-peptide, allowing less insulin use to achieve the same glycemic control as patients receiving placebo. A greater proportion of patients in the teplizumab groups were able to discontinue or use very low doses of insulin compared to the placebo group.  A reduced insulin requirement while maintaining glycemic control appears to support teplizumab having a biological effect.

In the safety analyses, the proportion of patients who had adverse events and serious adverse events was similar across the four study groups.  Rash was the most common clinical adverse event reported more frequently with teplizumab than placebo. Mild cytokine release syndrome was infrequent but greater in treatment groups compared to placebo. The safety profile was characterized by transient increases in some liver function test results and transient decreases in white cells that prevent infections. However, no increase in overall infections was seen.

"We are very pleased to have teplizumab Phase 3 data published in this prestigious journal," stated Dr. Scott Koenig, President and CEO of MacroGenics.  "Although the Protege study missed its primary endpoint, the data appear to indicate that teplizumab has a desired biological effect in certain subpopulations with a potentially meaningful therapeutic benefit for patients with recent-onset type 1 diabetes.  These groups in
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... --  Wellcentive , the industry leader in end-to-end ... today being named one of the four finalists ...  Sponsored by Intel, the world leader in computing ... companies developing leading-edge technology and unique approaches to ... Wellcentive,s Mason Beard , senior vice ...
(Date:11/18/2014)... Nov. 18, 2014 Respiratory Motion and IMI ... medical device and services providers in Japan ... Respiratory Motion,s innovative respiratory depression monitor, the ExSpiron™. As ... are working together to connect the clinical community in ... history of bringing innovative medical devices and new technology ...
(Date:11/18/2014)... 18, 2014 Investor-Edge has initiated coverage ... ), Geron Corporation (NASDAQ: GERN ), Tekmira Pharmaceuticals ... GALE ), and XOMA Corporation (NASDAQ: ... accessed at: http://investor-edge.com/register . The US markets ... as the Dow Jones Industrial Average finished at 17,647.75, up ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 2Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 3Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 4Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 5
(Date:11/21/2014)... The cost of diabetes care in the United States ... more than $322 billion annually, a new report shows. ... prediabetes care, which have risen 74 percent, and undiagnosed ... In 2012, excess medical costs and lost productivity ... American. That total includes $244 billion in medical costs ...
(Date:11/21/2014)... 2014 Richard Wolfe, co-founder and ... present advanced benefits administration strategies during the Game ... Leadership Summit. This Game Changer breakout session enables ... present cutting-edge solutions and best practices to top ... real-time data exchange between health and welfare benefits ...
(Date:11/21/2014)... Kansas City, Mo (PRWEB) November 21, 2014 ... has received the Get With The Guidelines®–Heart Failure ... improvement measures outlined by the American Heart Association/American ... guidelines for heart failure patients. , Get With ... that helps hospital teams provide the most up-to-date, ...
(Date:11/21/2014)... NJ (PRWEB) November 21, 2014 The ... homemade, high calorie dishes, plenty of gravy and a ... could be the best time of year to begin ... Diet Doc has uncovered the secret to losing unhealthy, ... the fattening holiday recipes. , The insight to Diet ...
(Date:11/21/2014)... Midway through the research period for the 2015 ... of Health Plans, preliminary data shows volatility in the ... is a comprehensive resource with enrollment data and contact ... 2015 edition will be available in February. ... Division, the company’s exclusive in-house research team, have identified ...
Breaking Medicine News(10 mins):Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 2Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 3Health News:Diet Doc Releases New Calorie Loading Diet Plans - the Perfect Way to Jump Start the Metabolism and Begin Weight Loss During Thanksgiving 4Health News:Data from Atlantic Information Services’s Forthcoming Directory Shows Volatility in U.S. Health Care Market 2
... , McALLEN, Texas, Dec. 3 The Ensign ... it has acquired three Texas skilled nursing facilities: the ... the 100-bed Alta Vista Rehabilitation & Healthcare in Brownsville; ... The acquisitions were effective December 1, 2009. , (Logo: ...
... , MINNEAPOLIS, Dec. 3 The American Association of Poison ... Minneapolis, Minnesota as an accredited poison control center - a ... AAPCC places the Hennepin Regional Poison Center among 58 accredited ... major accomplishment. It means we have met the national standards ...
... , NEW YORK, Dec. ... is available in its catalogue: , Point of Care ... review and analysis of the point of care (POC) diagnostics ... POC diagnostics industry , Covers federal regulation of POC ...
... , Statement by John Gay, Executive Director and ... to a new campaign launched today by the U.S. ... marketplace of "rogue" marketers selling steroids as dietary supplements, ... association representing retailers and manufacturers of dietary supplements and ...
... finds rising incidence of obesity could counter recent increases in ... health of the U.S. population has improved over the past ... but a new study suggests those gains might soon be ... level off or drop. , If current trends in both ...
... added batches now available, many more to come, NIH director ... stem cell lines have been added to the pool that ... lines will soon be made available, U.S. health officials announced ... lines approved for research funded by the U.S. National Institutes ...
Cached Medicine News:Health News:The Ensign Group Acquires Three Texas Skilled Nursing Facilities 2Health News:The Ensign Group Acquires Three Texas Skilled Nursing Facilities 3Health News:Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 2Health News:Reportlinker Adds Point of Care Diagnostics 2Health News:Reportlinker Adds Point of Care Diagnostics 3Health News:Reportlinker Adds Point of Care Diagnostics 4Health News:Reportlinker Adds Point of Care Diagnostics 5Health News:Reportlinker Adds Point of Care Diagnostics 6Health News:Reportlinker Adds Point of Care Diagnostics 7Health News:Reportlinker Adds Point of Care Diagnostics 8Health News:Reportlinker Adds Point of Care Diagnostics 9Health News:Reportlinker Adds Point of Care Diagnostics 10Health News:Reportlinker Adds Point of Care Diagnostics 11Health News:Reportlinker Adds Point of Care Diagnostics 12Health News:Natural Products Association Issues Statement on New Supplement Safety Campaign 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 2Health News:U.S. Approves New Stem Cell Lines for Publicly Funded Research 3
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
... Size: 3.0 x 7.5 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
Medicine Products: